Efficacy of ocrelizumab in relapsing multiple sclerosis – case report Case report
Article Sidebar
Main Article Content
Abstract
Multiple sclerosis is a progressive, inflammatory and degenerative disease affecting the central nervous system. This is a disease characterised by symptoms of unpredictable nature, which is due to its complex and dynamic underlying pathophysiology. Lymphocytes T and lymphocytes B play a major role in its pathogenesis. Considering this pathophysiological mechanism, the target of the novel drugs are mainly lymphocytes T and B. One of the drugs which acts by targeting lymphocytes B is ocrelizumab. It is a monoclonal antibody which, by binding to the right CD3+ and CD20+ receptors on lymphocytes, results in their decrease in the body, which to a significant extent inhibits the inflammatory process occurring in the course of the disease.
The article presents the case of a young man with relapsing-remitting multiple sclerosis where first line therapy with interferon β and glatiramer acetate failed to stop the disease activity, and it was ocrelizumab that proved effective.
The treatment of multiple sclerosis should be commenced immediately after its diagnosis is made, and in its active forms induction therapy proves much more effective than escalation therapy.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Barten LJ, Allington DR, Procacci KA, Rivey MP. New approaches in the management of multiple sclerosis. Drug Des Devel Ther 2010; 4: 343-366. DOI:10.2147/DDDT:S9331.
3. Munoz-Culla M, Irizar H, Otaegui G. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet 2013; 6: 63-73. DOI:10.214/TACG.S29107.
4. Koch MW, Metz LM, Kovalchuk O. Epigenetic changes in patient with multiple sclerosis. Nat Rev Neurol 2013; 9: 35-43. DOI:10.1038/nrneurol.2012.226.
5. Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717. DOI: 10.1002/1531-8249(200006)47:6<707:AIDANA3>3.0CO;2-Q.
6. Wekerie H. B cells in multiple sclerosis. Autoimmunity 2017; 50(1): 57-60.
7. Li R, Rezk A, Miyazaki Y et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7(310): 310ra166.
8. Genentech (2017) Ocrevus (prescribing information). Genentech, Inc., South San Francisco, CA, USA.
9. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol 2014; 27: 246-259. DOI: 10.1997/WCO.0000000000000096.
10. ChPL. Ocrevus .
11. Gingele S, Langer-Jacobus T, Konen FF, Hummert MW. Ocrelizumab Depletes CD20 + T Cells in Multiple Sclerosis Patients. Cells 2019; 8: 12. DOI: 10.3390/cells8010012.